1,721,061 research outputs found
Erratum: Alcoholic and nonalcoholic liver disease: Diagnostic assessment and therapeutic perspectives (BioMed Research International (2019) 2019 (8691502) DOI: 10.1155/2019/8691502)
No full textIn the article titled “Alcoholic and Nonalcoholic Liver Disease: Diagnostic Assessment and Therapeutic Perspectives” [1], the affiliation “University of Valencia, Hospital La Fe, Valencia, Spain” was incorrectly assigned to the author Dr. Marina Berenguer. The correct affiliations for this author are shown below, and they have been added as affiliations 6, 7, and 8 in the author information above: CIBER-EHD, Instituto de Salud Carlos III, Madrid, Spain Hepatology and Liver Transplantation Unit, IIS La Fe, Hospital Universitario y Politécnico La Fe, Valencia, Spain Faculty of Medicine, University of Valencia, Valencia, Spain
Reply to: “Hepatic encephalopathy and survival after transjugular intra-hepatic portosystemic shunt: Do spontaneous portosystemic shunts matter?”
No full text
Alcoholic and Nonalcoholic Liver Disease: Diagnostic Assessment and Therapeutic Perspectives
Full text linkAbstract non disponibil
The role of transjugular intrahepatic portosystemic shunt in patients with cirrhosis and ascites: Recent evolution and open questions
No full textIn selected patients with cirrhosis and ascites, transjugular intrahepatic portosystemic shunt (TIPS) placement improves control of ascites and may reduce mortality. In this review, we summarize the current knowledge concerning the use of TIPS for the treatment of ascites in patients with cirrhosis, from pathophysiology of ascites formation to hemodynamic consequences, patient selection, and technical issues of TIPS insertion. The combination of these factors is important to guide clinical decision-making and identify the best strategy for each individual patient. There is still a need to identify the best timing for TIPS placement in the natural history of ascites (recurrent vs. refractory) as well as which type and level of renal dysfunction is acceptable when TIPS is proposed for the treatment of ascites in cirrhosis. Future studies are needed to define the optimal stent diameter according to patient characteristics and individual risk of shunt-related side effects, particularly hepatic encephalopathy and insufficient cardiac response to hemodynamic consequences of TIPS insertion
When and how to treat acute hepatitis C?
No full textBackground: Appropriate treatment of acute hepatitis C is still a matter of controversy due to the lack of large controlled trials. Aim: To assess the effectiveness of interferon as treatment for acute hepatitis C by meta-analysis. Methods: MEDLINE search (1985-2002) was supplemented with manual searches of reference lists. Studies were included if they were controlled trials comparing interferon to no treatment and if they included patients with either post-transfusion or sporadic acute hepatitis C. Twelve trials were analyzed (414 patients). The outcome assessed was the sustained virological response (SVR) rate (undetectable hepatitis C virus RNA in serum at least 6 months after cessation of therapy). Results: Interferon significantly increased the SVR (risk difference 49%; 95% confidence interval 32.9-65%) in comparison to no treatment. The risk difference of SVR increased from 5 to 90% when trials were ordered by increasing interferon weekly dose. Delaying therapy by 8-12 weeks after the onset of disease does not compromise the SVR rate. Conclusions: Current evidence is sufficient to recommend interferon treatment of patients with acute hepatitis C. A later initiation of therapy yields the same likelihood of response as early treatment. A daily induction dose during the 1st month is the best option of treatment. © 2003 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved
- …
